Announcement on the progress of Shandong Buchang Pharmaceutical Co., Ltd.’s plan to give up the preferential transfer of equity interests in its controlled subsidiaries and related transactions
Securities code: 603858 Securities abbreviation: Buchang Pharmaceutical Announcement number: 2026-007
Shandong Buchang Pharmaceutical Co., Ltd.
Announcement on the progress of the plan to give up the preferential transfer of equity interests in controlled subsidiaries and related transactions
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
1. Transaction Overview
Liu Feng, a shareholder of Shaanxi Modern Innovation Traditional Chinese Medicine Research Institute Co., Ltd. (hereinafter referred to as "Shaanxi Modern Innovation"), a holding subsidiary of Shandong Buchang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Buchang Pharmaceutical"), plans to transfer his holdings of Shaanxi Modern Innovation 0.50% of the unpaid equity was transferred to Shi Dongpeng at a price of 0 yuan, and the company's wholly-owned subsidiary Shaanxi Buchang Pharmaceutical Co., Ltd. (hereinafter referred to as "Shaanxi Buchang Pharmaceutical") agreed to waive the right of priority; at the same time, the company's wholly-owned subsidiary Shaanxi Buchang Pharmaceutical Research Institute Co., Ltd. (hereinafter referred to as "Shaanxi Buchang Pharmaceutical") planned to transfer its 30.00% unpaid equity of Shaanxi Modern Innovation to Shaanxi Buchang Pharmaceutical at a price of 0 yuan. After the completion of the above-mentioned equity transfer, the company holds 86.50% equity of Shaanxi Modern Innovation through Shaanxi Buchang Pharmaceutical. For details, please refer to the "Announcement on the Plan to Give Up the Preferential Transfer of Equity Interests in its Controlled Subsidiaries and Related Transactions" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on July 9, 2025 (announcement number: 2025-132).
On September 5, 2025, Shaanxi Buchang Pharmaceutical and Shaanxi Buchang Pharmaceutical officially signed the "Equity Transfer Agreement Regarding Shaanxi Modern Innovative Traditional Chinese Medicine Research Institute Co., Ltd.". For details, please refer to the "Announcement on the Progress of the Plan to Give Up the Priority Transfer of Equity Interests in its Controlled Subsidiaries and Related Transactions" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on September 6, 2025 (announcement number: 2025-174).
2. Progress of this transaction
Recently, Shaanxi Modern Innovation has completed the industrial and commercial change registration procedures. The relevant information after the change is as follows: Name: Shaanxi Modern Innovative Traditional Chinese Medicine Research Institute Co., Ltd.
Type: Other limited liability company
Legal representative: Zhang Wei
Registered capital: RMB 20 million
Date of establishment: November 20, 2020
Residence: No. 123, West Extension Section of Weiyang West Road, Qindu District, Xianyang City, Shaanxi Province
Business scope: General projects: medical research and experimental development; technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; business management consulting; software development; software sales; big data services; sales agents; intelligent control system integration (the above projects are limited to the pharmaceutical field); Chinese herbal medicine cultivation; Chinese herbal medicine acquisition; manufacturing of special pharmaceutical equipment; sales of special pharmaceutical equipment; engineering management services ; Professional design services; Repair of special equipment; Sales of industrial automatic control system devices; Operational efficiency assessment services; Manufacturing of daily chemical products; Sales of daily chemical products; Manufacturing of drug testing instruments; Sales of drug testing instruments; Manufacturing of special equipment for environmental protection; Sales of special equipment for environmental protection; Research and development of resource recycling technology (except for projects that require approval according to law, independently carry out business activities with a business license and in accordance with the law). Licensed projects: pharmaceutical production; pharmaceutical wholesale; health food production; inspection and testing services; production of formula foods for special medical purposes; sales of formula foods for special medical purposes; construction project supervision; project cost consulting business; intelligent building system design; intelligent building engineering construction (projects that are subject to approval according to law can only be carried out with the approval of relevant departments, and specific business projects are subject to the approval results).
Equity structure:
Serial number Name of shareholder (name) Shareholding ratio before this transaction Shareholding ratio after this transaction 1 Shaanxi Buchang Pharmaceutical 56.50% 86.50%
2 Shaanxi Buchang Pharmaceutical 30.00% -
Shaanxi New Silk Road Quality Inspection Technology
3 10.00% 10.00%
Technology Assessment Ltd.
4 Wang Xifang 0.50% 0.50%
5 Wang Minggeng 0.50% 0.50%
6 Zheng Lingli 0.50% 0.50%
7 Zhang Weimin 0.50% 0.50%
8 Zhang Wei 0.50% 0.50%
9 Chen Yanbin 0.50% 0.50%
10 Liu Feng 0.50% -
11 Shi Dongpeng - 0.50%
Total - 100.00% 100.00%
Announcement is hereby made.
Board of Directors of Shandong Buchang Pharmaceutical Co., Ltd.
January 17, 2026